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Abstract Corticotropin releasing factor (CRF) induces a rapid,
within seconds, and dose-dependent increase in the intracellular
Ca2+ in both human and hamster melanoma cells. This effect is
inhibited by depletion of extracellular calcium using 3 mM
EGTA and is attenuated by the CRF receptor antagonist, K-
helical-CRF(9-41). Other peptides of the CRF superfamily,
sauvagine and urocortin, also induce increases in cytoplasmic
calcium concentration but at higher concentrations than CRF.
We conclude that malignant melanocytes express CRF receptors,
which are coupled to activation of plasma membrane calcium
channels.
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1. Introduction
It has been proposed that mammalian skin contains an
equivalent of ‘hypothalamic-pituitary axis’ composed of lo-
cally produced corticotropin-releasing factor (CRF) and pro-
opiomelanocortin (POMC) derived peptides as an important
mechanism of skin response to stress [1,2]. It is already well
documented that skin acts not only as a target for POMC
derived peptides including ACTH, MSH, and L-endorphin
but also as sites of their production [2^5]. Skin cells also
express the CRF gene and produce CRF peptide, which is
stimulated by ultraviolet radiation (UVR) [6^9]. Most re-
cently, expression of CRF-receptor (CRF-R) subtype-1
mRNA and protein was detected in the mammalian skin
[6,8^10].
The CRF signal is translated through an interaction with
G-protein coupled CFR-R [11]. At the central level this mech-
anism involves stimulation of adenylate cyclase, phospholi-
pase C or activation of calcium channels [11,12]. The CRF
receptors include those which show high speci¢city towards
CRF and receptors for which the speci¢c ligands are urocortin
or sauvagine peptides [13,14]. A potential functional role, if
any, of CRF receptors in the skin remain enigmatic. There-
fore, we have undertaken an e¡ort to de¢ne mechanisms of
signal transduction through the CRF receptors in malignant
human and hamster melanocytes.
2. Materials and methods
2.1. Materials
Human CRF synthesized by standard solid phase method was pur-
chased from Molecular Research Lab (North Carolina). Urocortin
and sauvagine were purchased from Peninsula Labs (Belmont, CA,
USA), K-helical-CRF(9-41) was a gift from Dr. Nicholas Ling (Neu-
rocrine Biosciences, San Diego, CA, USA). Ham F-10, Dulbecco’s
Modi¢ed Essential Medium (DMEM), fetal bovine serum, Hanks’
balanced salt solution (HBSS), antibiotic antimycotic mixture and
0.25% trypsin+1 mM EDTA were purchased from Gibco (Grand
Island, NY, USA). Fura-2/AM was from Molecular Probes (Oregon).
2.2. Cell culture
HaCaT immortalized keratinocytes (obtained from Dr. Higgins,
Albany Medical College, Albany, NY, USA), human melanoma
SK-MEL188 line (obtained from Dr. Chakraborty, Yale University,
New Haven, CT, USA) and hamster melanoma AbC1 were used for
the experiments. Semi-con£uent cultures of cells were maintained in
Ham F-10 or DMEM media with antibiotics in the presence of 10%
fetal bovine serum in 75-cm2 £asks at 37‡C in the presence of 5%
CO2, as described previously [7,15]. Media were changed every second
day. Melanoma cells were detached from the substratum by HBSS+1
mM EDTA and HaCaT keratinocytes were detached with 0.25% tryp-
sin+1 mM EDTA, then after centrifugation cells were washed in
HBSS and processed for calcium analysis.
2.3. Measurement of intracellular calcium £ux
The measurements of [Ca2]i were performed using methods de-
scribed previously [16]. Brie£y, cells were loaded with 2 M Fura-2/
AM (Molecular Probes, OR) for 1 h at room temperature. The un-
bound Fura-2 was washed using HBSS. Fura-2 loaded cells were
transferred to a £uorometer cuvette. Fluorescence signals were re-
corded using Hitachi Spectro£uorometer (Model F-2000) at excitation
wavelengths of 340 and 380 nm, and the emission measured at 540
nm. The cells were stimulated with di¡erent peptides after 90^100 s of
the initial response (basal). A peak elevation in [Ca2]i occurred im-
mediately after the addition of peptide. This peak elevation in [Ca2]i
was taken as the peptide-induced elevation and was used for calcium
analysis. The results were digitized and imported into a statistical
analysis program (SigmaPlot) for quantitative analysis. Integrated
[Ca2]i was estimated by calculating the area under the [Ca2]i re-
sponse curve over a period of 300^600 s after stimulation of the cells.
Statistical analyses were performed using the Student’s t-test. The
di¡erences were considered signi¢cant when P6 0.05.
3. Results and discussion
The basal [Ca2]i in control (unstimulated) human melano-
ma cells and HaCaT keratinocytes is 120 þ 20 nM
(mean þ S.E.) and in hamster melanoma cells is 200 þ 20 nM
(mean þ S.E.) per 2.5U106 cells. The addition of the peptides
to the cells results in a signi¢cant elevation in the [Ca2]i
(400^650 nM). As shown in Fig. 1A, an increase in [Ca2]i
is observed within 1^3 s following di¡erent doses of CRF
(1037 to 10312 M) in melanoma cells, and in HaCaT kerati-
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nocytes at concentration 1037 M. There is no stimulation after
addition of the solvent alone. Thus, this is a ¢rst demonstra-
tion that CRF has any e¡ect on malignant melanocytes in-
cluding an increase in [Ca2]i. The stimulatory e¡ect of CRF
on HaCaT keratinocytes is in agreement with data reported
by Kiang [17,18] who showed that CRF and CRF related
peptides can stimulate intracellular calcium raises in squa-
mous cell carcinoma line A431. However, we have discontin-
ued further experiments with HaCaT cells because of a di⁄-
culty in maintaining them in single cell suspension.
Intracellular calcium release following stimulation of di¡er-
ent concentrations of CRF in both human and hamster mel-
anoma cells is dose dependent and saturable reaching a pla-
teau at concentrations 1039 to 1037 M (Fig. 1 and Table 1),
which suggests that the increase in [Ca2]i is due to speci¢c
interaction of CRF with its receptor on the cell. This has been
con¢rmed by the use of CRF antagonist K-helical CRF(9-41)
[19] at concentrations 1039 and 1038 M. Higher concentra-
tions of K-helical CRF(9-41) (e.g. 1037 M) cause an increase
in [Ca2]i in a similar manner to CRF (results not shown).
The representative experiment showing an inhibitory e¡ect of
K-helical CRF(9-41) is presented in Fig. 2. In this assay the
average integrated [Ca2]i in cells after stimulation with 1039
M of CRF (area under curve 8.9U104 nM/s) on human mel-
anoma cells has been inhibited by one minute preincubation
with K-helical CRF(9-41) (1038 M) (area under curve
4.87U104 nM/s) (Fig. 2a,b). Similarly the e¡ect of 1039 M
of CRF (area under curve 5U104 nM/s of calcium) on ham-
ster melanoma cells is inhibited by preincubation with K-hel-
ical CRF(9-41) (1038 M) (area under curve 3.62U104 nM/s of
calcium) (Fig. 2aP,bP). Thus, preincubation with K-helical
CRF(9-41) reduces the calculated area under the curve by
4U104 nM/s of calcium in human melanoma cells and by
2.6U104 nM/s of calcium in hamster melanoma cells. This
inhibitory e¡ect has been reproduced in 6 independent experi-
ments (not shown). Thus, preincubation with K-helical
CRF(9-41) (1038 M) signi¢cantly decreases (P6 0.001) and
(P6 0.01) the CRF induced [Ca2]i by 70 þ 20% (n = 6) and
45 þ 10% (n = 6) in human and hamster melanoma cells, re-
spectively. Other peptides of the CRF superfamily, including
sauvagine and urocortin, also stimulate intracellular calcium
releases, however, at high concentrations, 1035^1037 M, in
human and hamster melanoma cells (Fig. 1B and Table 1).
Both peptides are without any e¡ect at concentrations 1039 M.
These results in conjunction with previous documentation of
the expression of CRF-R1 mRNA in mammalian skin [6^10]
show that the increases in [Ca2]i in human and hamster
malignant melanocytes are mediated through CRF receptors,
most likely CRF-R1.
The rapid increase of cytosolic Ca2, which peaks within 1^
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Fig. 1. The e¡ect of CRF and related peptides on [Ca2]i. A: Eleva-
tion of [Ca2]i stimulated by di¡erent doses of CRF in human (a^e)
and hamster (aP^dP) melanoma cells, and HaCaT keratinocytes (f),
measured by Fura-labeling at the time indicated by the arrow. B:
Elevation of [Ca2]i stimulated by urocortin and sauvagine in hu-
man (left panel) and hamster (right panel) melanoma cells.
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3 s of CRF stimulation (Fig. 1), reduces the likelihood that
the e¡ect is mediated through cAMP or inositol triphosphate
(IP3) mediated mechanisms. These pathways activate calcium
in£ux from the extracellular environment or activate release of
Ca2 from internal stores, respectively [12,20]. Stimulation of
either pathways, which are coupled to the CRF-R1 signal
transduction system at the central level [11,12], would require
a longer delay time of [Ca2]i than those observed in our
experiments [12,19,20]. The experiments showing that the cal-
cium chelator EGTA (3 mM) signi¢cantly inhibits the CRF-
induced [Ca2]i, which is most apparent in hamster cells (Fig.
3), suggests that an in£ux of calcium through the plasma
membrane channel is the major contributor to a prolonged
elevation in [Ca2]i in malignant melanocytes. Thus, part of
the CRF signaling in malignant melanocytes is coupled to
direct activation of plasma membrane Ca2 channels, which
is similar to e¡ects described in the pituitary cells [12,19,20].
Previously we documented production and release of CRF
in normal and malignant melanocytes [5,7], which was accom-
panied by an expression of CRF-R1 gene [5^7]. Moreover,
mammalian pigment cells express POMC gene and produce
POMC-derived ACTH, MSH and L-endorphin peptides [1^4].
In the present study we show that malignant melanocytes
contain functional CRF receptors. These observations raise
the possibility that the melanocyte/melanoma phenotype
may be regulated by autocrine mechanisms directly via an
activation of CRF receptors or indirectly by a CRF-stimu-
lated production of MSH or ACTH.
In summary, we have demonstrated that CRF and related
urocortin and sauvagine induce changes in the intracellular
calcium signaling in skin cells and that this e¡ect in malignant
melanocytes is mediated through a CRF-R which is predom-
inantly coupled to the plasma membrane Ca2 channels.
These results support our hypothesis that regulated local
CRH signals can play a role in skin physiology and pathology
and also set the background for further studies on molecular
mechanism of CRF signal transduction in this largest organ
of the body.
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Fig. 2. Inhibitory e¡ect of K-helical CRF(9-41) preincubation on
[Ca2]i response to CRF stimulation. Changes in [Ca2]i were moni-
tored using £uorescene [Ca2]i indicator dye, Fura-2, as outlined in
Section 2. Upper panel: CRF (1039 M) e¡ect without any pretreat-
ment; lower panel: CRF (1039 M) e¡ect after 1 min preincubation
with K-helical CRF(9-41) (1038 M).
Fig. 3. Elevation of [Ca2]i stimulated by CRF depends on external
Ca2. The e¡ect of chelation of external [Ca2]i by EGTA (3 mM)
(¢rst arrow) inhibited dramatically CRF induced (second arrow)
changes in [Ca2]i in human and hamster melanoma cells.
Table 1
Stimulation of cytosolic free calcium concentration in melanoma
cells by CRF related peptides
Addition (M) Stimulation above the basal level (%)
Hamster melanoma Human melanoma
CRF
10313 No e¡ect No e¡ect
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10310 303 þ 10 277 þ 10
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1037 490 þ 70 440 þ 30
1035 ND ND
Urocortin
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Sauvagine
10313 No e¡ect No e¡ect
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10310 No e¡ect No e¡ect
1039 No e¡ect No e¡ect
1037 326 þ 10 320 þ 30
1035 513 þ 30 275 þ 15
ND: not done. The stimulatory e¡ect is shown in relative units as %
of basal level (non-induced cells) and represents a mean þ S.D. from
four experiments.
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